Lucas C - Search Results

1

[Study of the clinical pharmacokinetics of fotemustine in various tumor indications].

Lokiec F, Beerblock K, Deloffre P, Lucas C, Bizzari JP. Lokiec F, et al. Among authors: lucas c. Bull Cancer. 1989;76(10):1063-9. Bull Cancer. 1989. PMID: 2635634 French.

2

[Interspecies comparison of pharmacokinetic parameters of fotemustine (nitrosourea S 10036): mice, rats, monkeys, dogs and man].

Lucas C, Ings B, Gray AJ, Deloffre P, Lokiec F, Campbell B, Beerblock K. Lucas C, et al. Bull Cancer. 1989;76(8):863-5. Bull Cancer. 1989. PMID: 2515897 French. No abstract available.

3

Activity and unexpected lung toxicity of the sequential administration of two alkylating agents--dacarbazine and fotemustine--in patients with melanoma.

Gerard B, Aamdal S, Lee SM, Leyvraz S, Lucas C, D'Incalci M, Bizzari JP. Gerard B, et al. Among authors: lucas c. Eur J Cancer. 1993;29A(5):711-9. doi: 10.1016/s0959-8049(05)80352-1. Eur J Cancer. 1993. PMID: 8471329

4

Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French cancer centre multicentric study.

Iliadis A, Launay-Iliadis MC, Lucas C, Fety R, Lokiec F, Tranchand B, Milano G. Iliadis A, et al. Among authors: lucas c. Eur J Cancer. 1996 Mar;32A(3):455-60. doi: 10.1016/0959-8049(95)00565-x. Eur J Cancer. 1996. PMID: 8814692

5

Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil.

Julia AM, Roché H, Berlion M, Lucas C, Milano G, Robert J, Bizzari JP, Canal P. Julia AM, et al. Among authors: lucas c. Br J Cancer. 1994 May;69(5):868-74. doi: 10.1038/bjc.1994.168. Br J Cancer. 1994. PMID: 8180016 Free PMC article.

6

Pharmacokinetic profile of fotemustine in rat plasma by electrochemical detection.

Bartosek I, Corada M, Dallarda S, Lucas C, Deloffre P, Guaitani A. Bartosek I, et al. Among authors: lucas c. Xenobiotica. 1991 Feb;21(2):235-42. doi: 10.3109/00498259109039465. Xenobiotica. 1991. PMID: 2058178

7

In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells-reversal of multidrug resistance by sera from phase I-treated patients.

Soudon J, Berlion M, Lucas C, Haddad P, Bizzari JP, Calvo F. Soudon J, et al. Among authors: lucas c. Cancer Chemother Pharmacol. 1995;36(3):195-203. doi: 10.1007/BF00685846. Cancer Chemother Pharmacol. 1995. PMID: 7781138 Clinical Trial.

8

Human pharmacokinetics of a new Vinca alkaloid S 12363 with use of a monoclonal antibody-based radio- or enzyme immunoassay.

Lelievre E, Guillaudeux J, Cardona H, Bourguignat A, Lokiec F, Solere P, Lucas C, Sauveur C. Lelievre E, et al. Among authors: lucas c. Cancer Res. 1993 Aug 1;53(15):3536-40. Cancer Res. 1993. PMID: 8339259 Clinical Trial.

9

Hepatic intra-arterial infusion of fotemustine: pharmacokinetics.

Fety R, Lucas C, Solere P, Cour V, Vignoud J. Fety R, et al. Among authors: lucas c. Cancer Chemother Pharmacol. 1992;31(2):118-22. doi: 10.1007/BF00685097. Cancer Chemother Pharmacol. 1992. PMID: 1451232

10

Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas.

Tranchand B, Lucas C, Biron P, Giroux B, Gordon B, Richards R, Solere P, Roux N, Evene E, Mornex F, et al. Tranchand B, et al. Among authors: lucas c. Cancer Chemother Pharmacol. 1993;32(1):46-52. doi: 10.1007/BF00685875. Cancer Chemother Pharmacol. 1993. PMID: 8462123 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,231 results

Search Page

Filters